The introduction of HER2-targeted therapy for breast and gastric patients with ERBB2
(HER2) amplification/overexpression has led to dramatic improvements in oncologic …

Background FGFR alterations are reported across various malignancies and might act as
oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine …

Since June 2019, under the umbrella of the national health insurance system, Japan has
started cancer genomic medicine (CGM) with comprehensive genomic profiling (CGP) tests …

Cell death escape is one of the most prominent features of tumor cells and closely linked to
the dysregulation of members of the Bcl-2 family of proteins. Among those, the anti-apoptotic …

The common mutation BRAFV600 in primary melanomas activates the mitogen-activated
protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the …

Abstract Purpose: Cell-free DNA (cfDNA) sequencing provides a noninvasive method for
obtaining actionable genomic information to guide personalized cancer treatment, but the …

Genome sequencing studies have identified millions of somatic variants in cancer, but it
remains challenging to predict the phenotypic impact of most. Experimental approaches to …

The incidence of esophagogastric cancer is rapidly rising, but only a minority of patients
derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 …

A multitude of cellular processes involve biomolecular condensates, which has led to the
suggestion that diverse pathogenic mutations may dysregulate condensates. Although proof …

RAS family variants—most of which involve KRAS—are the most commonly occurring
hotspot mutations in human cancers and are associated with a poor prognosis. For almost …